Search results for: Oncology
Filter search results
Paula Lorgelly Joins the OHE Team as Deputy Director
4 December 2015
…areas of health economics: the determinants of health, economic evaluation and outcome measurement. Most recently she has been working in the clinical areas of oncology, including genomic testing; maternal mental…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…by use of value-based assessment of health and health-related outcomes and by value-based pricing. Additional incentives may be needed for ultra-orphan drugs in oncology and other diseases. Effective management of…
Chris Sampson
9 October 2017
…clinical contexts, including diabetes, oncology, sleep, and neonatal care, but his passion is for mental health; Chris is the Lead Convener for IHEA’s Mental Health Economics Special Interest Group. As…
Chris Skedgel
15 July 2019
…He has been a Lead Economic Reviewer for the pan-Canadian Oncology Drug Review (pCODR) and the Canadian Common Drug Review (CDR) and has led the development of NICE submissions in…
Priscila Radu
20 September 2021
Priscila has published research on various health economics topics, including changes in HTA methods in several regions, assessment pathways for precision oncology, and regulatory landscape of digital health in the…
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
…elsewhere*. Key observations from the literature include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are…
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
…be agreed upon, building on learnings from the oncology space. Finally, Oriol addressed the “elephant in the room”: affordability from the payer perspective. He proposed moving away from the Fee…
Around The World in HTAs: Italy – What’s Next?
20 April 2023
…on Pricing of Medicines Reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023 Jan;41(1):107-117. Russo, P., Marcellusi, A., Zanuzzi, M., et al. Drug Prices and Value of Oncology Drugs in…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…patient per indication, and is the necessary data being generated routinely or requiring ad hoc intervention? There is a UK collaboration to pilot, in oncology, the feasibility of MIP in…